HC Wainwright reiterated their buy rating on shares of Stemline Therapeutics (NASDAQ:STML) in a research report sent to investors on Monday.
A number of other research analysts have also recently issued reports on the stock. BidaskClub cut shares of Stemline Therapeutics from a buy rating to a hold rating in a report on Saturday, June 16th. Cowen reaffirmed a buy rating on shares of Stemline Therapeutics in a report on Friday, June 15th. ValuEngine cut shares of Stemline Therapeutics from a strong-buy rating to a buy rating in a report on Friday, June 15th. Roth Capital assumed coverage on shares of Stemline Therapeutics in a report on Tuesday, June 12th. They issued a buy rating and a $30.00 price target for the company. Finally, Wedbush raised their price target on shares of Stemline Therapeutics from $20.00 to $22.00 and gave the stock an outperform rating in a report on Tuesday, May 29th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $30.00.
Shares of STML opened at $17.10 on Monday. The company has a market capitalization of $537.36 million and a price-to-earnings ratio of -5.82. Stemline Therapeutics has a twelve month low of $7.30 and a twelve month high of $20.55.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.02. Stemline Therapeutics had a negative net margin of 4,689.63% and a negative return on equity of 101.93%. equities research analysts anticipate that Stemline Therapeutics will post -2.72 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Knott David M raised its holdings in shares of Stemline Therapeutics by 20.0% in the first quarter. Knott David M now owns 90,000 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 15,008 shares during the last quarter. Virtus Fund Advisers LLC purchased a new position in shares of Stemline Therapeutics during the fourth quarter worth $374,000. Citadel Advisors LLC purchased a new position in shares of Stemline Therapeutics during the first quarter worth $8,948,000. venBio Select Advisor LLC purchased a new position in shares of Stemline Therapeutics during the first quarter worth $8,022,000. Finally, Royce & Associates LP purchased a new position in shares of Stemline Therapeutics during the fourth quarter worth $106,000. 66.91% of the stock is owned by institutional investors and hedge funds.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.